• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » FDA issues guidelines to address COVID-19 variants

FDA issues guidelines to address COVID-19 variants

February 22, 2021 By Sean Whooley Leave a Comment

SARS-CoV-2
SARS-CoV-2 image from Wikipedia

The FDA today issued guidance for medical product developers to address the emergence of variants of SARS-CoV-2, which causes COVID-19.

Variants of the virus have been detected in multiple countries across the globe, including the U.S., and they pose a major threat to potentially ending the COVID-19 pandemic as protocols such as mask-wearing and hand-washing remain in place and vaccines are being distributed.

“The FDA is committed to identifying efficient ways to modify medical products that either are in the pipeline or have been authorized for emergency use to address emerging variants,” acting FDA Commissioner Dr. Janet Woodcock said in a news release. “We know the country is eager to return to a new normal and the emergence of the virus variants raises new concerns about the performance of these products. By issuing these guidances, we want the American public to know that we are using every tool in our toolbox to fight this pandemic, including pivoting as the virus adapts.

“We need to arm health care providers with the best available diagnostics, therapeutics and vaccines to fight this virus. We remain committed to getting these life-saving products to the frontlines.”

Having already updated guidance in October to offer insights on variants to vaccine developers, the FDA said that, currently, available information suggests that authorized vaccines developed by Pfizer (NYSE:PFE)/BioNTech (NSDQ:BNTX) and Moderna (NSDQ:MRNA) remain effective in protecting the American public against circulating strains of COVID-19.

However, the FDA stressed that an emergence of SARS-CoV-2 variant(s) in the U.S. that are moderately or fully resistant to the current vaccines may require developers to tailor the vaccines to defend against those variants.

The FDA’s updated guidance recommends modifications to authorized vaccines and expects that manufacturing information will remain generally the same for such vaccines from the same manufacturers. Effectiveness must be supported by data from clinical immunogenicity studies which would compare the recipient’s immune response to virus variants induced by the modified version against the immune response to the authorized vaccine.

Further discussion will be held on the matter to decide if modified COVID-19 vaccines may be authorized without the need for clinical studies in the future, the FDA said.

For COVID-19 diagnostics, the FDA already issued a safety alert to warn that the presence of variants in a sample could potentially change the performance of a test, having already identified a few that are impacted by mutations, although the impact does not appear to be significant at present.

The guidance recommends that test developers consider the potential for future viral genetic mutations when designing their test while conducting their own routine monitoring to evaluate the potential impact of new mutations on the diagnostics.

Finally, the FDA issued new guidance and revised a second guidance all centering around COVID-19 monoclonal antibody therapeutics.

The new guidance recommends efficient approaches to the generation of non-clinical, clinical and chemistry, manufacturing and controls data that support emergency use authorization for a developer of such therapeutics, as the administration has been made aware that some antibodies currently authorized are less active against some of the variants.

Additionally, the second guidance, which covers drugs and biological products more broadly, was updated to address the variants and the availability of authorized vaccines as the FDA outlined clinical trials for therapeutics, including patient populations, efficacy endpoints, safety considerations and statistical considerations.

“With these guidances, the FDA is encouraging developers of drugs or biological products targeting SARS-CoV-2 to continuously monitor genomic databases for emerging SARS-CoV-2 variants and evaluate phenotypically any specific variants in the product target that are becoming prevalent or could potentially impact its activity,” the FDA wrote in the release.

Filed Under: Business/Financial News, Diagnostics, Featured, Food & Drug Administration (FDA), Genomics/Molecular Diagnostics, Pharmaceutical, Regulatory/Compliance Tagged With: BioNTech, coronavirus, COVID-19, COVID-19 vaccine, COVID-19 variants, FDA, Moderna, Pfizer

In case you missed it

  • ControlRad gains clearance for imaging tech to sell to Boston Sci
  • Capsule lands Frost & Sullivan award for remote ventilator monitor
  • Philips debuts AI-enhanced imaging platform
  • Pulmatrix completes $40M offering, updates product pipeline timetable
  • Medtronic launches IDE trial for AFib tech
  • Medtronic hiring Walmart exec to run its supply chain
  • An Overview of IEC 60601-1 3rd Edition, 2nd Amendment
  • Report: Permira eyeing LivaNova purchase
  • Amgen to acquire Five Prime Therapeutics for $1.9B
  • Medtronic wins city council approval for 42-acre campus in Colorado
  • Conformis dips 9% on Street-beating Q4 results
  • Becton Dickinson acquires smart medication device maker GSL Solutions
  • FDA clears once-daily ADHD capsule from Corium
  • Philips and Disney want to make MRIs easier for children: Here’s how
  • Origami Surgical gains FDA clearance for robotic suturing devices
  • Hillrom execs change their minds on BardyDx acquisition
  • Wearable infusion device maker Bexson Biomedical appoints SVP of drug delivery

RSS From Medical Design & Outsourcing

  • Philips and Disney want to make MRIs easier for children: Here’s how
    Royal Philips (NYSE:PHG) announced today that it is teaming up with Disney to test the effects of custom-made animation to create a relaxing atmosphere for young patients. Amsterdam-based Philips will collaborate with The Walt Disney Company EMEA to see whether the animation, including specially-made Disney stories within Philips’ Ambient Experience, creates a relaxing atmosphere to improve… […]
  • Origami Surgical gains FDA clearance for robotic suturing devices
    Origami Surgical today announced that the FDA has granted 510(k) clearance for three new types of sutures for its StitchKit robotic surgery platform. The company describes StitchKit as a patented suture delivery and retrieval system designed so sutures are efficiently inserted and needles are safely removed from the surgical field. StitchKit also allows the robotic… […]
  • NAMSA acquires American Preclinical
    Contract research organization NAMSA today announced its acquisition of Minneapolis-based American Preclinical Services (APS). This purchase follows NAMSA’s acquisition of New York-based Syntactx, a clinical research services CRO, in January. The acquisition will provide NAMSA customers with a broader range of laboratory models and analysis tools, including innovative surgical instrumentation and several state-of-the-art catheterization labs,… […]
  • 5 reasons Medtronic’s CEO is optimistic about the future
    Nearly a year after Geoff Martha took over the corner office at Medtronic, the world’s largest medical device company is transforming. In a recent interview with our DeviceTalks Weekly podcast, Martha detailed Medtronic‘s major reorganization, its shift in corporate culture and more. Martha was also highly pleased about Medtronic’s recent Q3 earnings results. Here are… […]
  • Medtronic is changing a lot: Here’s what you need to know
    CEO Geoff Martha says Medtronic‘s ongoing corporate restructuring will position the company to compete better with medical device rivals, freeing the front-line forces from earlier entanglements. But the change will also create new opportunities for Medtronic employees at the company and elsewhere. In a far-ranging interview with the DeviceTalks Weekly podcast, Martha reviewed the company’s… […]
  • Pharma’s been slow to adopt Industry 4.0 — but that could change
    The pharma industry has been relatively slow to embrace concepts such as Industry 4.0, but COVID-19 is serving as a catalyst for sweeping changes within the industry. The philosophy has roots in a German framework that prioritizes digitization to drive manufacturing efficiency, promising that cyber-physical systems will usher in the next industrial revolution. The Industry… […]
  • Ambu single-use endoscope wins Frost & Sullivan innovation award
    Frost & Sullivan today announced that it awarded Ambu with a 2021 Global New Product Innovation Award. Ambu received the award for its single-use flexible endoscopes that are designed to make the devices safe, affordable and accessible. It has aView and aBox all-in-one video displays that eliminate the traditional video endoscopy tower size and expense to be… […]
  • Could this hydrogel repair a broken heart?
    European researchers have developed an injectable hydrogel that could help repair and prevent further heart muscle damage after a heart attack. The therapeutic effect of multiple injections of this hydrogel into the cardiac tissue was assessed during the first preclinical study of its kind, demonstrating its efficacy for cardiac tissue remodeling following a heart attack,… […]
  • How EtO plants can avoid lawsuits, cope with stricter regulation
    If EtO industry actors take certain targeted steps now, they can minimize legal exposure, more efficiently manage litigation and be better situated for compliance once new federal regulations are established. Karen Cullinane, Goldberg Segalla The use of ethylene oxide (EtO) to sterilize medical devices came under renewed scrutiny after the Environmental Protection Agency concluded in… […]
  • FDA authorizes Q-Collar to help protect athletes’ brains
    The FDA announced today that it authorized the Q-Collar made by Q30 Sports Science for protecting the brain during sports activities. Q30 Sports Science’s Q-Collar is a C-shaped collar worn around the neck designed to apply compressive force to the neck and increase blood volume to help reduce movement of the brain within the cranial… […]
  • The top 7 medtech CEO quotes on COVID-19, one year later
    The latest earnings season has provided insights into the future of medtech in the COVID-19 landscape and what certain sectors are seeing as vaccines start to roll out. Since the start of the pandemic, 113.1 million COVID-19 cases have been reported worldwide, according to Johns Hopkins University School of Medicine. The U.S. leads the world… […]

Reader Interactions

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS